Dementia Treatment Market Size & Share 2024 – 2032

Dementia Treatment Market Size

Dementia Treatment Market size was valued at USD 17.7 billion in 2023 and is expected to exhibit growth at a CAGR of 7.6% from 2024 – 2032. High market growth can be attributed to the ongoing advancements in medical research, increasing prevalence of dementia, rising geriatric population, and growing demand for multimodal and personalized therapies, among other contributing factors.

Moreover, the global population is aging rapidly, with a significant increase in the proportion of older adults. Aging is the primary risk factor for dementia, and as the population ages, the prevalence of dementia is expected to rise. For instance, according to a recent United Nations (UN) research report, the number of people aged 65 and over globally is predicted to treble over the next three decades. The senior population is expected to reach 1.6 billion by 2050, accounting for more than 16% of the worldwide population.
 

This demographic trend creates a growing market for dementia treatments as the demand for effective therapies to manage symptoms and improve quality of life increases.
 

Dementia treatment refers to a broad range of therapeutic interventions aimed at managing the symptoms, slowing the progression, and improving the quality of life of individuals diagnosed with dementia. Dementia is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, impaired reasoning, and changes in behavior and personality.
 

Dementia Treatment Market Trends

The market is experiencing several notable trends that are shaping its growth and development. Factors such as growing focus on early detection and intervention, advancements in precision medicine, rise of disease-modifying therapies, and surging need of integrated digital health solutions, among other factors are propelling the industry growth.
 

• Further, there is a growing emphasis on early detection of dementia through screening programs, biomarker research, and diagnostic innovations. Early diagnosis enables timely intervention with pharmacological and non-pharmacological treatments, lifestyle modifications, and support services, potentially delaying disease progression and improving outcomes.
   
• Moreover, digital health technologies, such as telemedicine, remote monitoring, mobile apps, wearable medical devices, and artificial intelligence in healthcare, are revolutionizing dementia care delivery and management. These technologies enable remote assessment, monitoring, and communication between patients, caregivers, and healthcare providers, enhancing access to care and optimizing treatment outcomes, thereby aforementioned factors are expected to drive the market.
   

Dementia Treatment Market Analysis

Based on drug class segment, the market is categorized into cholinesterase inhibitors, NMDA receptor antagonist, combination drugs, glutamate inhibitors, MAO inhibitors, and other drug classes. The cholinesterase inhibitors segment dominated the market in 2023 with a revenue of USD 8 billion.
 

• ChEIs, including drugs such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), have been extensively studied in clinical trials and have shown consistent efficacy in improving cognitive function and slowing the progression of symptoms in individuals with Alzheimer's disease. Their established efficacy and safety profile make them a preferred choice for healthcare providers in the management of dementia.
   
• Additionally, ongoing research efforts are focused on improving the efficacy, safety, and tolerability of ChEIs, as well as exploring novel formulations and drug delivery methods. Newer generation ChEIs with enhanced pharmacokinetic properties, such as once-daily dosing or transdermal patches, may offer improved convenience and adherence for patients and caregivers, further driving their utilization in clinical practice, thus leading to the segmental growth.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on indication segment, the dementia treatment market is classified into alzheimer’s disease, parkinson disease dementia, vascular dementia, lewy body dementia, frontotemporal dementia (FTD), and other indications. The alzheimer’s disease segment dominated the market in 2023 with a market share of 42%.
 

• The primary risk factor for Alzheimer's disease is age, and with global populations aging rapidly, there is a corresponding increase in the prevalence of Alzheimer's disease. According to the Alzheimer's Association data published in 2023, alzheimer's disease affects around 6.7 million Americans aged 65 and older, with a projected increase to 13.8 million by 2060. As people live longer, the number of individuals affected by Alzheimer's disease is expected to rise, driving the demand for treatments and care services.
   
• Furthermore, alzheimer's disease represents a substantial and growing burden on individuals, families, healthcare systems, and society as a whole. The economic and social costs associated with Alzheimer's disease, including healthcare expenditures, caregiver burden, and lost productivity, underscore the urgent need for effective treatments and interventions. This is anticipated to boost the segmental growth in the market.
   

Based on route of administration, the dementia treatment market is classified into oral, injectable, and transdermal patch. The oral segment dominated the market and is expected to grow at a pace of 7.5% CAGR between 2024 – 2032.
 

• Oral medications offer a convenient and accessible route of administration for individuals with dementia and their caregivers. Compared to other routes, such as intravenous or intramuscular injections, oral administration is non-invasive and can be easily managed at home or in long-term care settings, enhancing patient adherence and treatment compliance.
   
• Moreover, the availability of oral medications provides healthcare providers with a range of treatment options to address the diverse symptoms and clinical manifestations of dementia. Oral medications targeting cognitive symptoms, such as ChEIs and NMDA receptor antagonists, as well as behavioral and psychological symptoms, such as antipsychotics and antidepressants, allow for individualized treatment plans tailored to each patient's specific needs and preferences.
   

Based on distribution channel, the dementia treatment market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2023 and is anticipated to reach USD 20.5 billion by the end of forecast period.
 

• Hospital pharmacies are responsible for ensuring the safe, effective, and appropriate use of medications for patients with dementia. They play a key role in comprehensive medication management, including medication reconciliation, dosage adjustments, drug interactions screening, and patient education, to optimize treatment outcomes and minimize adverse effects.
   
• Furthermore, hospital pharmacies collaborate closely with other healthcare professionals, including physicians, nurses, pharmacists, social workers, and allied health professionals, to provide comprehensive care for patients with dementia. Multidisciplinary team meetings, care conferences, and treatment planning sessions facilitate communication, coordination, and shared decision-making, ensuring holistic and patient-centered care.
   

North America dementia treatment market accounted for USD 6.7 billion market revenue in 2023 and is anticipated to grow at CAGR of 7.4% between 2024 – 2032 period.
 

• North America is home to a robust pharmaceutical industry, comprising multinational corporations, biotechnology companies, and academic research centers. Pharmaceutical companies in the region invest heavily in dementia research and drug development, leveraging their expertise, resources, and partnerships to advance potential treatments through preclinical and clinical stages of development.
   
• Furthermore, the region boasts advanced healthcare infrastructure, including well-established healthcare systems, academic medical centers, research institutions, and pharmaceutical industries. This infrastructure supports the development, adoption, and dissemination of innovative treatments, technologies, and care delivery models for dementia, leading to the regional growth.
   

The U.S. held a dominant position in the dementia treatment market, with a revenue of USD 6.2 billion in 2023.
 

• The U.S. leads the world in technological innovation, particularly in healthcare. The country is at the forefront of research and development in areas such as neuroscience, genetics, imaging, digital health, and artificial intelligence, which drive advancements in dementia diagnosis, treatment, and care. Technological innovations enable remote monitoring, telemedicine, digital biomarkers, predictive analytics, and personalized medicine approaches in dementia management.
   
• Moreover, the U.S. academic institutions and research centers excel in dementia research, clinical trials, and translational science. Collaboration between academia, industry, and government fosters innovation and accelerates progress in understanding the underlying mechanisms of dementia, identifying novel drug targets, and developing innovative treatment approaches.
   

Germany dementia treatment market is projected to grow remarkably in the coming years.
 

• Germany boasts a well-developed healthcare infrastructure, including universal health coverage, well-equipped hospitals, research institutions, and pharmaceutical industries. This infrastructure supports the development, adoption, and dissemination of innovative treatments, technologies, and care delivery models for dementia.
   
• The country has a comprehensive healthcare system with universal health coverage and a statutory health insurance system. Reimbursement policies and coverage decisions influence market access for dementia treatments, affecting prescribing patterns, patient access, and pharmaceutical pricing strategies.
   

Japan holds a dominant position in the Asia Pacific dementia treatment market.
 

• Japan is a leader in technological innovation, particularly in healthcare. The country invests in research and development in areas such as neuroscience, robotics, assistive devices, digital health, and artificial intelligence, which drive advancements in dementia diagnosis, treatment, and care. Technological innovations enable remote monitoring, telemedicine, digital biomarkers, predictive analytics, and personalized medicine approaches in dementia management.
   
• Moreover, increased awareness about dementia and its impact on individuals and society has led to the implementation of public health initiatives aimed at promoting brain health, dementia prevention, and early detection. Government campaigns, community education programs, and public-private partnerships raise awareness about risk factors, warning signs, and available resources for dementia diagnosis, treatment, and support.
   

Dementia Treatment Market Share

The dementia treatment industry is characterized by a diverse landscape of pharmaceutical companies, biotechnology firms, and research organizations vying for market share. Established players in market holds significant positions with their approved medications targeting cognitive symptoms, while newer entrants and academic institutions contribute to innovation with novel therapeutic approaches. Market share dynamics are influenced by factors such as product efficacy, safety profile, pricing strategies, regulatory approvals, and market access, driving competition and market segmentation across regions and therapeutic segments within the market.
 

Dementia Treatment Market Companies

Prominent players operating in the dementia treatment industry include:

• AbbVie Inc.
• Biogen
• Cipla Inc.
• Daiichi Sankyo Company, Limited
• Eisai Co., Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Otsuka Pharmaceutical Co., Ltd.
• Sun Pharmaceutical Industries Ltd.
   

Dementia Treatment Industry News:

• In April 2024, Eisai Co., Ltd. and Biogen Inc. announced that Eisai has filed a Supplemental Biologics License Application (sBLA) to the U.S. Food and FDA for monthly intravenous (IV) maintenance dose of lecanemab-irmb. LEQEMBI is recommended for the treatment of Alzheimer's disease (AD) in individuals with moderate cognitive impairment or mild dementia (also known as early AD).
   
• In May 2023, Eli Lilly and Company announced the positive results of the TRAILBLAZER-ALZ 2 Phase 3 study showing that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
   

The dementia treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Cholinesterase inhibitors
• NMDA receptor antagonist
• Combination drugs
• Glutamate inhibitors
• MAO inhibitors
• Other drug classes

Market, By Indication

• Alzheimer’s disease
• Parkinson disease dementia
• Vascular dementia
• Lewy body dementia
• Frontotemporal dementia (FTD)
• Other indications

Market, By Route of Administration

• Oral
• Injectable
• Transdermal patch

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa